

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No. 50623.379		Application No. 09/918,365	
US Patent and Trademark Office				Applicant Michal et al.			
<b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)				Filing Date July 30, 2001		Group Art Unit 1762	
<b>U.S. PATENT DOCUMENTS</b>							
Order Number Initial	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate	
A1	2,072,303	3/2/37	Herrmann et al.				
A2	2,386,454	10/9/45	Frosch et al.				
A3	3,773,737	11/20/73	Goodman et al.				
A4	3,849,514	11/19/74	Gray, Jr. et al.				
A5	4,226,243	10/7/80	Shalaby et al.				
A6	4,329,383	5/11/82	Joh				
A7	4,343,931	8/10/82	Barrows				
A8	4,529,792	7/16/85	Barrows				
A9	4,611,051	9/9/86	Hayes et al.				
A10	4,656,242	4/7/87	Swan et al.				
A11	4,733,665	3/29/88	Palmaz				
A12	4,800,882	1/31/89	Gianturco				
A13	4,882,168	11/21/89	Casey et al.				
A14	4,886,062	12/12/89	Wiktor				
A15	4,931,287	6/5/90	Bae et al.				
A16	4,941,870	7/17/90	Okada et al.				
A17	4,977,901	12/18/90	Ofstead				
A18	5,019,096	5/28/91	Fox, Jr. et al.				
A19	5,100,992	3/31/92	Cohn et al.				
A20	5,112,457	5/12/92	Marchant				
A21	5,133,742	7/28/92	Pinchuk				
A22	5,163,952	11/17/92	Froix				
A23	5,165,919	11/24/92	Sasaki et al.				
A24	5,219,980	6/15/93	Swidler				
A25	5,258,020	11/2/93	Froix				

A26	5,272,012	12/21/93	Opolski			
A27	5,292,516	3/8/94	Viegas et al.			
A28	5,298,260	3/29/94	Viegas et al.			
A29	5,300,295	4/5/94	Viegas et al.			
A30	5,306,501	4/26/94	Viegas et al.			
A31	5,306,786	4/26/94	Moens et al.			
A32	5,328,471	7/12/94	Slepian			
A33	5,330,768	7/19/94	Park et al.			
A34	5,380,299	1/10/95	Fearnott et al.			
A35	5,417,981	5/23/95	Endo et al.			
A36	5,447,724	9/5/95	Helmus et al.			
A37	5,455,040	10/3/95	Marchant			
A38	5,462,990	10/31/95	Hubbell et al.			
A39	5,464,650	11/7/95	Berg et al.			
A40	5,485,496	1/16/96	Lee et al.			
A41	5,516,881	5/14/96	Lee et al.			
A42	5,569,463	10/29/96	Helmus et al.			
A43	5,578,073	11/26/96	Haimovich et al.			
A44	5,584,877	12/17/96	Miyake et al.			
A45	5,605,696	2/25/97	Eury et al.			
A46	5,607,467	3/4/97	Froix			
A47	5,609,629	3/11/97	Fearnott et al.			
A48	5,610,241	3/11/97	Lee et al.			
A49	5,616,338	4/1/97	Fox, Jr. et al.			
A50	5,624,411	4/29/97	Tuch			
A51	5,628,730	5/13/97	Shapland et al.			
A52	5,644,020	7/1/97	Timmermann et al.			
A53	5,649,977	7/22/97	Campbell			
A54	5,658,995	8/19/97	Kohn et al.			
A55	5,667,767	9/16/97	Greff et al.			
A56	5,670,558	9/23/97	Onishi et al.			
A57	5,674,242	10/7/97	Phan et al.			

A58	5,679,400	10/21/97	Tuch		
A59	5,700,286	12/23/97	Tartaglia et al.		
A60	5,702,754	12/30/97	Zhong		
A61	5,711,958	1/27/98	Cohn et al.		
A62	5,716,981	2/10/98	Hunter et al.		
A63	5,721,131	2/24/98	Rudolph et al.		
A64	5,723,219	3/3/98	Kolluri et al.		
A65	5,735,897	4/7/98	Buirge		
A66	5,746,998	5/5/98	Torchilin et al.		
A67	5,759,205	6/2/98	Valentini		
A68	5,776,184	7/7/98	Tuch		
A69	5,783,657	7/21/98	Pavlin et al.		
A70	5,788,979	8/4/98	Alt et al.		
A71	5,800,392	9/1/98	Racchini		
A72	5,820,917	10/13/98	Tuch		
A73	5,824,048	10/20/98	Tuch		
A74	5,824,049	10/20/98	Ragheb et al.		
A75	5,830,178	11/3/98	Jones et al.		
A76	5,837,008	11/17/98	Berg et al.		
A77	5,837,313	11/17/98	Ding et al.		
A78	5,849,859	12/15/98	Acemoglu		
A79	5,851,508	12/22/98	Greff et al.		
A80	5,854,376	12/29/98	Higashi		
A81	5,857,998	1/12/99	Barry		
A82	5,858,746	1/12/99	Hubbell et al.		
A83	5,865,814	2/2/99	Tuch		
A84	5,869,127	2/9/99	Zhong		
A85	5,873,904	2/23/99	Ragheb et al.		
A86	5,876,433	3/2/99	Lunn		
A87	5,877,224	3/2/99	Brocchini et al.		
A88	5,879,713	3/9/99	Roth et al.		
A89	5,902,875	5/11/99	Roby et al.		

A90	5,905,168	5/18/99	Dos Santos et al.
A91	5,910,564	6/8/99	Gruning et al.
A92	5,914,387	6/22/99	Roby et al.
A93	5,919,893	7/6/99	Roby et al.
A94	5,925,720	7/20/99	Kataoka et al.
A95	5,932,299	8/3/99	Katoot
A96	5,955,509	9/21/99	Webber et al.
A97	5,958,385	9/28/99	Tondeur et al.
A98	5,962,138	10/5/99	Kolluri et al.
A99	5,971,954	10/26/99	Conway et al.
A100	5,980,928	11/9/99	Terry
A101	5,980,972	11/9/99	Ding
A102	5,997,517	12/7/99	Whitbourne
A103	6,010,530	1/4/00	Goicoechea
A104	6,011,125	1/4/00	Lohmeijer et al.
A105	6,015,541	1/18/00	Greff et al.
A106	6,033,582	3/7/00	Lee et al.
A107	6,034,204	3/7/00	Mohr et al.
A108	6,042,875	3/28/00	Ding et al.
A109	6,051,576	4/18/00	Ashton et al.
A110	6,051,648	4/18/00	Rhee et al.
A111	6,054,553	4/25/00	Groth et al.
A112	6,056,993	5/2/00	Leidner et al.
A113	6,060,451	5/9/00	DiMaio et al.
A114	6,060,518	5/9/00	Kabanov et al.
A115	6,080,488	6/27/00	Hostettler et al.
A116	6,096,070	8/1/00	Ragheb et al.
A117	6,099,562	8/8/00	Ding et al.
A118	6,110,188	8/29/00	Narciso, Jr.
A119	6,110,483	8/29/00	Whitbourne et al.
A120	6,113,629	9/5/00	Ken
A121	6,120,491	9/19/00	Kohn et al.

A122	6,120,536	9/19/00	Ding et al.		
A123	6,120,788	9/19/00	Barrows		
A124	6,120,904	9/19/00	Hostettler et al.		
A125	6,121,027	9/19/00	Clapper et al.		
A126	6,129,761	10/10/00	Hubbell		
A127	6,136,333	10/24/00	Cohn et al.		
A128	6,143,354	11/7/00	Koulik et al.		
A129	6,153,252	11/28/00	Hossainy et al.		
A130	6,159,978	12/12/00	Myers et al.		
A131	6,165,212	12/26/00	Dereume et al.		
A132	6,172,167	1/9/01	Stapert et al.		
A133	6,177,523	1/23/01	Reich et al.		
A134	6,180,632	1/30/01	Myers et al.		
A135	6,203,551	3/20/01	Wu		
A136	6,211,249	4/3/01	Cohn et al.		
A137	6,214,901	4/10/01	Chudzik et al.		
A138	6,231,600	5/15/01	Zhong		
A139	6,240,616	6/5/01	Yan		
A140	6,245,753	6/12/01	Byun et al.		
A141	6,245,760	6/12/01	He et al.		
A142	6,248,129	6/19/01	Froix		
A143	6,251,136	6/26/01	Guruwaiya et al.		
A144	6,254,632	7/3/01	Wu et al.		
A145	6,258,121	7/10/01	Yang et al.		
A146	6,258,371	7/10/01	Koulik et al.		
A147	6,262,034	7/17/01	Mathiowitz et al.		
A148	6,270,788	8/7/01	Koulik et al.		
A149	6,277,449	8/21/01	Kolluri et al.		
A150	6,283,947	9/4/01	Mirzaee		
A151	6,283,949	9/4/01	Roorda		
A152	6,284,305	9/4/01	Ding et al.		

A153	6,287,628	9/11/01	Hossainy et al.		
A154	6,299,604	10/9/01	Ragheb et al.		
A155	6,306,176	10/23/01	Whitbourne		
A156	6,331,313	12/18/01	Wong et al.		
A157	6,335,029	1/1/02	Kamath et al.		
A158	6,344,035	2/5/02	Chudzik et al.		
A159	6,346,110	2/12/02	Wu		
A160	6,358,556	3/19/02	Ding et al.		
A161	6,379,381	4/30/02	Hossainy et al.		
A162	6,387,379	5/14/02	Goldberg et al.		
A163	6,395,326	5/28/02	Castro et al.		
A164	6,419,692	7/16/02	Yang et al.		
A165	6,451,373	9/17/02	Hossainy et al.		
A166	6,482,834	11/19/02	Spada et al.		
A167	6,494,862	12/17/02	Ray et al.		
A168	6,503,538	1/7/03	Chu et al.		
A169	6,503,556	1/7/03	Harish et al.		
A170	6,503,954	1/7/03	Bhat et al.		
A171	6,506,437	1/14/03	Harish et al.		
A172	6,524,347	2/25/03	Myers et al.		
A173	6,527,801	3/4/03	Dutta		
A174	6,527,863	3/4/03	Pacetti et al.		
A175	6,528,526	3/4/03	Myers et al.		
A176	6,530,950	3/11/03	Alvarado et al.		
A177	6,530,951	3/11/03	Bates et al.		
A178	6,540,776	4/1/03	Sanders Millare et al.		
A179	6,544,223	4/8/03	Kokish		
A180	6,544,543	4/8/03	Mandrusov et al.		
A181	6,544,582	4/8/03	Yoe		
A182	6,555,157	4/29/03	Hossainy		
A183	6,558,733	5/6/03	Hossainy et al.		

A184	6,565,659	5/20/03	Pacetti et al.	6/28/01
A185	6,572,644	6/3/03	Moein	6/27/01
A186	6,585,755	7/1/03	Jackson et al.	6/29/01
A187	6,585,765	7/1/03	Hossainy et al.	6/29/00
A188	6,585,926	7/1/03	Mirzaee	8/31/00
A189	6,605,154	8/12/03	Villareal	5/31/01
A190	6,623,448	9/23/03	Slater	3/30/01
A191	6,625,486	9/23/03	Lundkvist et al.	4/11/01
A192	6,645,135	11/11/03	Bhat	3/30/01
A193	6,645,195	11/11/03	Bhat et al.	1/5/01
A194	6,656,216	12/2/03	Hossainy et al.	6/29/01
A195	6,656,506	12/2/03	Wu et al.	5/09/01
A196	6,660,034	12/9/03	Mandrusov et al.	4/30/01
A197	6,663,662	12/16/03	Pacetti et al.	12/28/00
A198	6,666,880	12/23/03	Chiu et al.	6/19/01
A199	6,673,154	1/6/04	Pacetti et al.	6/28/01
A200	6,673,385	1/6/04	Ding et al.	6/28/01
A201	6,689,099	2/10/04	Mirzaee	2/27/01
A202	6,695,920	2/24/04	Pacetti et al.	6/27/01
A203	6,706,013	3/16/04	Bhat et al.	6/29/01
A204	6,712,845	3/30/04	Hossainy	4/24/01
A205	6,713,119	3/30/04	Hossainy et al.	12/23/99
A206	6,716,444	4/6/04	Castro et al.	9/28/00
A207	6,740,040	5/25/04	Mandrusov et al.	1/30/01
A208	6,743,462	6/1/04	Pacetti	5/31/01
A209	6,749,626	6/15/04	Bhat et al.	11/17/00
A210	6,758,859	7/6/04	Dang et al.	10/30/00
A211	6,759,054	7/6/04	Chen et al.	12/28/00

	A212	6,764,505	7/20/04	Hossainy et al.			4/12/01
	A213	6,887,485	5/3/05	Fitzhugh et al.			5/25/01
	A214	6,899,731	5/31/05	Li et al.			1/2/01
U.S. PATENT APPLICATION PUBLICATION DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A215	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
	A216	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A217	2001/0007083	7/5/01	Roorda			12/21/00
	A218	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A219	2002/0120326	8/29/02	Michal			12/22/00
	A220	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A221	2001/0018469	8/30/01	Chen et al.			12/28/00
	A222	2002/0123801	9/5/02	Pacetti et al.			12/28/00
	A223	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A224	2003/0032767	2/13/03	Tada et al.			2/5/01
	A225	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A226	2002/0142039	10/3/02	Claude			3/30/01
	A227	2002/0155212	10/24/02	Hossainy			4/24/01
	A228	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A229	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A230	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A231	2002/0007214	1/17/02	Falotico			5/7/01
	A232	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A233	2002/0016625	2/7/02	Falotico et al.			5/7/01
	A234	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A235	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A236	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A237	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A238	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A239	2002/0071822	6/13/02	Uhrich			7/27/01
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation
							Yes No



B1	2001-190687	7/17/01	Japan (English Abstract)				
B2	DE 42 24 401	1/27/94	Germany				
B3	EP 0 301 856	2/1/89	EPO				
B4	EP 0 396 429	11/7/90	EPO				
B5	EP 0 514 406	11/25/92	EPO				
B6	EP 0 604 022	6/29/94	EPO				
B7	EP 0 623 354	11/9/94	EPO				
B8	EP 0 665 023	8/2/95	EPO				
B9	EP 0 701 802	3/20/96	EPO				
B10	EP 0 716 836	6/19/96	EPO				
B11	EP 0 809 999	12/3/97	EPO				
B12	EP 0 832 655	4/1/98	EPO				
B13	EP 0 850 651	7/1/98	EPO				
B14	EP 0 879 595	11/25/98	EPO				
B15	EP 0 910 584	4/28/99	EPO				
B16	EP 0 923 953	6/23/99	EPO				
B17	EP 0 953 320	11/3/99	EPO				
B18	EP 0 970 711	1/12/00	EPO				
B19	EP 0 982 041	3/1/00	EPO				
B20	EP 1 023 879	8/2/00	EPO				
B21	EP 1 192 957	4/3/02	EPO				
B22	EP 1 273 314	1/8/03	EPO				
B23	SU 790725	2/9/83	SU (English Abstract)				
B24	SU 811750	9/23/83	SU (English Abstract)				
B25	SU 872531	10/15/81	SU (English Abstract)				
B26	SU 876663	10/30/81	SU (English Abstract)				
B27	SU 905228	2/15/82	SU (English Abstract)				
B28	SU 1016314	5/7/83	SU (English Abstract)				
B29	SU 1293518	2/28/87	SU (English Abstract)				
B30	WO 91/12846	9/5/91	PCT				
B31	WO 94/09760	5/11/94	PCT				
B32	WO 95/10989	4/27/95	PCT				

B33	WO 95/24929	9/21/95	PCT				
B34	WO 96/40174	12/19/96	PCT				
B35	WO 97/10011	3/20/97	PCT				
B36	WO 97/45105	12/4/97	PCT				
B37	WO 97/46590	12/11/97	PCT				
B38	WO 98/08463	3/5/98	PCT				
B39	WO 98/17331	4/30/98	PCT				
B40	WO 98/32398	7/30/98	PCT				
B41	WO 98/36784	8/27/98	PCT				
B42	WO 99/01118	1/14/99	PCT				
B43	WO 99/38546	8/5/99	PCT				
B44	WO 99/63981	12/16/99	PCT				
B45	WO 00/02599	1/20/00	PCT				
B46	WO 00/12147	3/9/00	PCT				
B47	WO 00/18446	4/6/00	PCT				
B48	WO 00/64506	11/2/00	PCT				
B49	WO 01/01890	1/11/01	PCT				
B50	WO 01/15751	3/8/01	PCT				
B51	WO 01/17577	3/15/01	PCT				
B52	WO 01/45763	6/28/01	PCT				
B53	WO 01/49338	7/12/01	PCT				
B54	WO 01/51027	7/19/01	PCT				
B55	WO 01/74414	10/11/01	PCT				
B56	WO 02/003890	1/17/02	PCT				
B57	WO 02/026162	4/4/02	PCT				
B58	WO 02/034311	5/2/02	PCT				
B59	WO 02/056790	7/25/02	PCT				
B60	WO 02/058753	8/1/02	PCT				
B61	WO 02/102283	12/27/02	PCT				
B62	WO 03/000308	1/3/03	PCT				
B63	WO 03/022323	3/20/03	PCT				
B64	WO 03/028780	4/10/03	PCT				

	B65	WO 03/037223	5/8/03	PCT				
	B66	WO 03/039612	5/15/03	PCT				
	B67	WO 03/080147	10/2/03	PCT				
	B68	WO 03/082368	10/9/03	PCT				
	B69	WO 04/000383	12/31/03	PCT				
	B70	WO 04/009145	1/29/04	PCT				
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)								
	C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061848202959">http://www.dialogweb.com/cgi/document?req=1061848202959</a> , printed 8/25/03 (2 pages).						
	C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061847871753">http://www.dialogweb.com/cgi/document?req=1061847871753</a> , printed 8/25/03 (2 pages).						
	C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent</i> (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						
	C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061846017752">http://www.dialogweb.com/cgi/document?req=1061846017752</a> , printed 8/25/03 (2 pages).						
	C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).						
	C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).						
	C7	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).						
	C8	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).						
	C9	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).						
	C10	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).						
	C11	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).						
	C12	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).						
	C13	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).						
	C14	Huang et al., <i>Biodegradable Polymers Derived from Aminoacids</i> , Macromol. Symp. 144, 7-32 (1999).						
	C15	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).						
	C16	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).						
	C17	Katsarava et al., <i>Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(<math>\alpha</math>-amino acid)<math>\alpha,\omega</math>-Alkylene Diesters, and Aliphatic Dicarboxylic Acids</i> , Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).						
	C18	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).						

C19	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
C20	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).
C21	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
C22	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
C23	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
C24	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
C25	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087. (Dec. 1998).
C26	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
C27	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).
C28	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
C29	Saotome, et al., <i>Novel Enzymatically Degradable Polymers Comprising <math>\alpha</math>-Amino Acid, 1,2-Ethanediol, and Adipic Acid</i> , Chemistry Letters, pp. 21-24, (1991).
C30	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
C31	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
C32	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
C33	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).

EXAMINER

ERMA CAMERON

DATE CONSIDERED

8/15/2007

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.